Twist Bioscience Corporation Announces Pricing of Initial Public Offering at $14.00 Per Share

SAN FRANCISCO--(BUSINESS WIRE)-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA, today announced that it has priced its initial public offering of 5,000,000 shares of its common stock at a price to the public of $14.00 per share, before underwriting discounts and commissions. All of the shares of common stock are being offered by Twist. The shares are expected to begin trading on the Nasdaq Global Select Market on October 31, 2018 under the ticker symbol “TWST.” The closing of the offering is expected to occur on November 2, 2018, subject to customary closing conditions.

In addition, Twist has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares at the initial public offering price, less the underwriting discounts and commissions.

J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as joint book-running managers for the proposed offering. Allen & Company LLC and Robert W. Baird & Co. Incorporated are acting as co-managers.

The offering is being made only by means of a prospectus. A final prospectus relating to the offering may be obtained, when available, from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; or Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or by telephone at (631) 274-2806.

A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission and can be accessed through the SEC’s website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Twist Bioscience Corporation

We are leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of our platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. We are leveraging our unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sample (NGS) preparation, and antibody libraries for drug discovery and development. We are also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. We make products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181030006209/en/